2022. Optimizing the treatment sequence: the cumulative clinical benefit of treatment initiation with deucravacitinib versus apremilast over 52 weeks in patients with moderate to severe plaque psoriasis from the POETYK PSO-1 trial. SKIN The Journal of Cutaneous Medicine. 6, 6 (Nov. 2022), s62. DOI:https://doi.org/10.25251/skin.6.supp.62.